Novo Nordisk Inc. Appoints Eddie Li as Vice President, Regulatory Affairs
PRINCETON, N.J., Sept. 7, 2011 /PRNewswire/ -- Novo Nordisk Inc. announced today that Dr. Eddie Li, has been appointed to join the diabetes leader as Vice President, Regulatory Affairs starting September 12.
Reporting to Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs for North America, Dr. Li brings over 20 years of industry, public sector, and academic experience in the field of regulatory affairs and safety. He'll be leading Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.
"Eddie has worked within the FDA and other pharmaceutical peers so he brings a wealth of experience to Novo Nordisk. He comes to us at a critical time in our company as our portfolio continues to grow," said Anne Phillips, M.D., corporate vice president, Clinical, Medical and Regulatory Affairs. "The regulatory environment is becoming increasingly complex, and Eddie's background suits our needs to have a senior leader as our main point of contact with the FDA."
Originally trained in medicine and toxicology, Dr. Li has an extensive background in the pharmaceutical industry, joining Novo Nordisk from Sanofi, where he most recently was global head of regulatory affairs for one of its largest therapy areas. He has also worked at Johnson & Johnson and AstraZeneca. He also served as a staff reviewer at the FDA.
Eddie studied in the Shanghai First Medical College. He subsequently completed his Ph.D. in Toxicology at the University of Arkansas for Medical Sciences, and also studied in an M.B.A. program at the University of Delaware.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit www.novonordisk-us.com.
SOURCE Novo Nordisk Inc.